EPO Patent Bulletin: Method for Determining Anticancer Treatment Efficacy

The European Patent Office has published patent application EP4634406A1 detailing a method for determining and improving the potential efficacy of anticancer treatments. The patent application lists ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS and other research institutions as applicants.

EPO Patent Publication: Novel Human Antiviral Genes

The European Patent Office published patent application EP4630033A1 on March 18, 2026, detailing novel human antiviral genes related to prokaryotic systems. The application was filed by Institut National de la Santé et de la Recherche Médicale, Université Paris Cité, and Institut Curie.

Extracellular Matrix Compounds for Localized Therapeutic Agent Loading

The European Patent Office has published patent application EP4630443A1 concerning extracellular matrix binding compounds for localized loading of therapeutic or diagnostic agents. The application was filed by Kamino ApS and lists Andreas Lodberg, Christian Brix Folsted Andersen, and Marco Eijken as inventors.

EPO Patent: Novel Compounds as NLRP3 Inhibition Modulators

The European Patent Office has published a new patent application (EP4630417A1) for novel compounds that act as modulators of NLRP3 inhibition. The patent application was filed by F. Hoffmann-La Roche AG and lists multiple inventors.

EPO Patent EP4630402A1: Sulfonyl Derivatives as CCR6 Inhibitors

The European Patent Office has published patent application EP4630402A1 concerning sulfonyl derivatives as CCR6 inhibitors, with F. Hoffmann-La Roche AG listed as the applicant. This publication details chemical compounds and their potential therapeutic applications.

EPO Patent EP4630419A1: Novel Pyrazine-Carboxamide-Imidazopyridine Derivatives

The European Patent Office has published patent application EP4630419A1 for novel pyrazine-carboxamide-imidazopyridine derivatives, with Boehringer Ingelheim International GmbH listed as the applicant. The patent covers potential applications in treating neurological disorders and cancer.

Recombinant receptors binding B cell activation factor receptor patent

Recombinant receptors binding B cell activation factor receptor patent

Ofgem Consultation on Future Interconnection Strategy

Ofgem has issued a call for input seeking views on its proposals for a future strategic approach to interconnection in Great Britain. The consultation focuses on the delivery and financing approaches for future interconnection projects identified through National Energy System Operator (NESO) strategic planning.

ASIC Corporations Amendment Instrument 2026/186

The Australian Securities and Investments Commission (ASIC) has issued the Corporations Amendment Instrument 2026/186, amending existing corporate regulations. This instrument is authorised by the Corporations Act 2001 and is effective from March 25, 2026.

ASIC Corporations (Consents to Statements) Instrument 2026/89

The Australian Securities and Investments Commission (ASIC) has issued the ASIC Corporations (Consents to Statements) Instrument 2026/89, which takes effect on March 25, 2026. This legislative instrument is authorised by the Corporations Act 2001.